Literature DB >> 29545348

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.

Pierre Feugier1, Thérèse Aurran2, Béatrice Mahé3, Remi Letestu4, Florence Nguyen-Khac5, Bruno Cazin6, Olivier Tournilhac7, Hervé Maisonneuve8, Olivier Casasnovas9, Alain Delmer10, Véronique Leblond11, Bruno Royer12, Bernadette Corront13, Sylvie Chevret14, Roselyne Delépine15, Sandrine Vaudaux16, Eric Van Den Neste17, Marie-Christine Béné3, Florence Cymbalista4, Damien Ross-Weil11, Stéphane Leprêtre16.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29545348      PMCID： PMC6029553          DOI： 10.3324/haematol.2017.183350

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.

Authors:  Romain Guièze; Pauline Robbe; Ruth Clifford; Sophie de Guibert; Bruno Pereira; Adele Timbs; Marie-Sarah Dilhuydy; Maite Cabes; Loïc Ysebaert; Adam Burns; Florence Nguyen-Khac; Frédéric Davi; Lauren Véronèse; Patricia Combes; Magali Le Garff-Tavernier; Véronique Leblond; Hélène Merle-Béral; Reem Alsolami; Angela Hamblin; Joanne Mason; Andrew Pettitt; Peter Hillmen; Jenny Taylor; Samantha J L Knight; Olivier Tournilhac; Anna Schuh
Journal:  Blood       Date:  2015-08-27       Impact factor: 22.113

3.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

Review 4.  The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.

Authors:  Alan P Skarbnik; Stefan Faderl
Journal:  Ther Adv Hematol       Date:  2016-12-01

5.  Minimal residual disease is an independent predictor for 10-year survival in CLL.

Authors:  Marwan Kwok; Andy C Rawstron; Abraham Varghese; Paul A S Evans; Sheila J M O'Connor; Chi Doughty; Darren J Newton; Paul Moreton; Peter Hillmen
Journal:  Blood       Date:  2016-10-03       Impact factor: 22.113

6.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Valeria Spina; Alessio Bruscaggin; Sara Monti; Carmela Ciardullo; Clara Deambrogi; Hossein Khiabanian; Roberto Serra; Francesco Bertoni; Francesco Forconi; Luca Laurenti; Roberto Marasca; Michele Dal-Bo; Francesca Maria Rossi; Pietro Bulian; Josep Nomdedeu; Giovanni Del Poeta; Valter Gattei; Laura Pasqualucci; Raul Rabadan; Robin Foà; Riccardo Dalla-Favera; Gianluca Gaidano
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

7.  The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.

Authors:  Fie Juhl Vojdeman; Mars B Van't Veer; Geir E Tjønnfjord; Maija Itälä-Remes; Eva Kimby; Aaron Polliack; Ka L Wu; Jeanette K Doorduijn; Wendimagegn G Alemayehu; Shulamiet Wittebol; Tomas Kozak; Jan Walewski; Martine C J Abrahamse-Testroote; Marinus H J van Oers; Christian Hartmann Geisler
Journal:  Leuk Lymphoma       Date:  2016-08-02

8.  Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

Authors:  Stephane Lepretre; Therese Aurran; Beatrice Mahé; Bruno Cazin; Olivier Tournilhac; Herve Maisonneuve; Olivier Casasnovas; Alain Delmer; Veronique Leblond; Bruno Royer; Bernadette Corront; Sylvie Chevret; Roselyne Delépine; Sandrine Vaudaux; Eric Van Den Neste; Marie Christine Béné; Remi Letestu; Florence Cymbalista; Pierre Feugier
Journal:  Blood       Date:  2012-02-14       Impact factor: 22.113

9.  An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.

Authors:  Marco Montillo; Alessandra Tedeschi; Valeria Belsito Petrizzi; Francesca Ricci; Monica Crugnola; Mauro Spriano; Pierangelo Spedini; Fiorella Ilariucci; Lilj Uziel; Immacolata Attolico; Eleonora Vismara; Angelo De Blasio; Alfonso Zaccaria; Enrica Morra
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

10.  Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.

Authors:  Peter Hillmen; Aleksander B Skotnicki; Tadeusz Robak; Branimir Jaksic; Anna Dmoszynska; Jingyang Wu; Cynthia Sirard; Jiri Mayer
Journal:  J Clin Oncol       Date:  2007-11-05       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.